Literature DB >> 19690853

(68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Valentina Ambrosini, Maria Cristina Marzola, Domenico Rubello, Stefano Fanti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19690853     DOI： 10.1007/s00259-009-1247-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  26 in total

Review 1.  Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.

Authors:  Nasim Khan; Noboru Oriuchi; Tetsuya Higuchi; Keigo Endo
Journal:  Cancer Control       Date:  2005-10       Impact factor: 3.302

2.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.

Authors:  S Hoegerle; C Altehoefer; N Ghanem; I Brink; E Moser; E Nitzsche
Journal:  Eur J Nucl Med       Date:  2001-01

3.  The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.

Authors:  D Eidelberg; J R Moeller; V Dhawan; J J Sidtis; J Z Ginos; S C Strother; J Cedarbaum; P Greene; S Fahn; D A Rottenberg
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

4.  Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.

Authors:  J C Reubi; J A Chayvialle; B Franc; R Cohen; C Calmettes; E Modigliani
Journal:  Lab Invest       Date:  1991-04       Impact factor: 5.662

5.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

Review 6.  Current approaches to medullary thyroid carcinoma, sporadic and familial.

Authors:  Elizabeth A Fialkowski; Jeffrey F Moley
Journal:  J Surg Oncol       Date:  2006-12-15       Impact factor: 3.454

7.  Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.

Authors:  M Diehl; J H Risse; K Brandt-Mainz; M Dietlein; K H Bohuslavizki; P Matheja; H Lange; J Bredow; C Körber; F Grünwald
Journal:  Eur J Nucl Med       Date:  2001-11

8.  Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors.

Authors:  Raffaele Ciampi; Agnese Vivaldi; Cristina Romei; Alberto Del Guerra; Piero Salvadori; Barbara Cosci; Aldo Pinchera; Rossella Elisei
Journal:  Mol Cell Endocrinol       Date:  2008-05-14       Impact factor: 4.102

9.  PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA.

Authors:  Carine Pestourie; Benoît Thézé; Bertrand Kuhnast; Stéphane Le Helleix; Karine Gombert; Frédéric Dollé; Bertrand Tavitian; Frédéric Ducongé
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.

Authors:  A Faggiano; F Grimaldi; L Pezzullo; M G Chiofalo; C Caracò; N Mozzillo; G Angeletti; F Santeusanio; G Lombardi; A Colao; N Avenia; P Ferolla
Journal:  Endocr Relat Cancer       Date:  2008-11-12       Impact factor: 5.678
View more
  4 in total

1.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

2.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

3.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Authors:  Giorgio Treglia; Paola Castaldi; Maria Felicia Villani; Germano Perotti; Chiara de Waure; Angelina Filice; Valentina Ambrosini; Nadia Cremonini; Monica Santimaria; Annibale Versari; Stefano Fanti; Alessandro Giordano; Vittoria Rufini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-06       Impact factor: 9.236

4.  Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients.

Authors:  Bilge Volkan-Salancı; Pınar Özgen Kıratlı
Journal:  Mol Imaging Radionucl Ther       Date:  2015-06-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.